Compare NVAX & AWF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NVAX | AWF |
|---|---|---|
| Founded | 1987 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 924.4M |
| IPO Year | 1995 | N/A |
| Metric | NVAX | AWF |
|---|---|---|
| Price | $6.75 | $10.68 |
| Analyst Decision | Hold | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | ★ 3.3M | 190.0K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.57% |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $1,064,651,000.00 | N/A |
| Revenue This Year | $58.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.22 | ★ N/A |
| Revenue Growth | ★ 20.27 | N/A |
| 52 Week Low | $5.01 | $9.20 |
| 52 Week High | $11.55 | $10.67 |
| Indicator | NVAX | AWF |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 40.48 |
| Support Level | $6.36 | $10.61 |
| Resistance Level | $6.76 | $10.71 |
| Average True Range (ATR) | 0.22 | 0.06 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 47.39 | 26.69 |
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Alliancebernstein Glb High Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its primary investment objective is to seek high current income, and secondarily, capital appreciation. The fund invests in debt securities, including Sovereign Debt Obligations and corporate debt, denominated in non-U.S. currencies as well as in the U.S. Dollar. It may invest without limit in emerging and developed markets and debt securities of U.S. and non-U.S. corporate issuers.